Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $7.26 in the prior trading day, Cytek BioSciences Inc (NASDAQ: CTKB) closed at $5.68, down -21.76%. In other words, the price has decreased by -$21.76 from its previous closing price. On the day, 1.52 million shares were traded. CTKB stock price reached its highest trading level at $6.93 during the session, while it also had its lowest trading level at $5.619.
Ratios:
Our goal is to gain a better understanding of CTKB by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 25.44. For the most recent quarter (mrq), Quick Ratio is recorded 5.47 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on December 14, 2023, initiated with a Overweight rating and assigned the stock a target price of $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 19 ’24 when Yan Ming sold 20,000 shares for $5.87 per share. The transaction valued at 117,400 led to the insider holds 5,988,502 shares of the business.
Yan Ming sold 1,900 shares of CTKB for $13,304 on Apr 09 ’24. The CHIEF TECHNOLOGY OFFICER now owns 6,008,502 shares after completing the transaction at $7.00 per share. On Mar 18 ’24, another insider, Yan Ming, who serves as the CHIEF TECHNOLOGY OFFICER of the company, sold 20,000 shares for $6.77 each. As a result, the insider received 135,400 and left with 6,030,402 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 731646464 and an Enterprise Value of 468385280. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.64 while its Price-to-Book (P/B) ratio in mrq is 1.91. Its current Enterprise Value per Revenue stands at 2.328 whereas that against EBITDA is -30.902.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.42, which has changed by -0.1263538 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $9.33, while it has fallen to a 52-week low of $4.66. The 50-Day Moving Average of the stock is -12.84%, while the 200-Day Moving Average is calculated to be -4.01%.
Shares Statistics:
The stock has traded on average 696.76K shares per day over the past 3-months and 715240 shares per day over the last 10 days, according to various share statistics. A total of 129.77M shares are outstanding, with a floating share count of 116.78M. Insiders hold about 9.34% of the company’s shares, while institutions hold 58.05% stake in the company. Shares short for CTKB as of 1735603200 were 3483815 with a Short Ratio of 5.00, compared to 1732838400 on 3952746. Therefore, it implies a Short% of Shares Outstanding of 3483815 and a Short% of Float of 3.4799999999999995.
Earnings Estimates
The current rating of Cytek BioSciences Inc (CTKB) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0.04, with high estimates of $0.05 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.18 and -$0.05 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.2, with 4.0 analysts recommending between $0.37 and $0.13.
Revenue Estimates
5 analysts predict $61.49M in revenue for the current quarter. It ranges from a high estimate of $63.5M to a low estimate of $59.5M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $58.6MFor the next quarter, 5 analysts are estimating revenue of $49.24M. There is a high estimate of $50.52M for the next quarter, whereas the lowest estimate is $47M.
A total of 6 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $206.4M, while the lowest revenue estimate was $203.09M, resulting in an average revenue estimate of $204.71M. In the same quarter a year ago, actual revenue was $193.39MBased on 6 analysts’ estimates, the company’s revenue will be $227.95M in the next fiscal year. The high estimate is $235M and the low estimate is $217.51M.
